ZSP1602 / Guangdong Zhongsheng Pharma - LARVOL DELTA

Zhongsheng Pharmaceutical: Announcement on Obtaining Invention Patent Certificate [Google translation] (Stockstar) - "Recently, Guangdong Zhongsheng Pharmaceutical Co., Ltd...received a letter from the People's Republic of China. Invention patent certificate issued by the State Intellectual Property Office....This patent is the company’s innovative drug for the treatment of malignant tumors such as small cell lung cancer, gastric cancer, and esophageal cancer. The crystal form patent of the ZSP1602 project is the core patent of the project. The ZSP1602 project series crystal form patents have currently been granted patents in China and Taiwan."

Patent • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer

A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=65; Recruiting; Sponsor: Guangdong Zhongsheng Pharmaceutical Co., Ltd.; Trial completion date: Dec 2020 ➔ Jul 2021; Trial primary completion date: Nov 2020 ➔ Jul 2021

Clinical • Trial completion date • Trial primary completion date • Basal Cell Carcinoma • Brain Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Glioblastoma • Lung Cancer • Medulloblastoma • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • GLI1